VentiRx Pharmaceuticals Commences Phase I Clinical Trial Of VTX-2337, A Novel TLR8 Agonist For The Treatment Of Oncology

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today that it has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer. The multi-center clinical trial is being conducted at the Mayo Clinic Arizona and TGen Drug Development Services (TD2) both in Scottsdale, Arizona.

More: continued here

Filed under: Cancer on December 6th, 2008